About DBV Technologies

Company Description

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential clinical applications. Viaskin is based on epicutaneous immunotherapy, or EPIT™, a method of delivering biologically active compounds to the immune system through intact skin. With this new class of patch-based, non-invasive product candidates, the Company is dedicated to safely transforming the care of food-allergic patients. DBV’s food allergy programs include ongoing clinical trials of Viaskin™ Peanut in children. In addition to food allergies, Viaskin technology is also being investigated as a treatment option for other immunological disorders. Additional applications for Viaskin, such as use as a diagnostic tool for non-IgE-mediated milk allergy or as a non-invasive method for delivering vaccines against certain diseases, are also being investigated. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ.

Year founded

2002

Served area

Worldwide

Headcount

92

Headquarters

177-181 Avenue Pierre Brossolette, 92120 Montrouge – France

Shareholder information

Shares outstanding

61,132,775

IPO

March 29, 2012

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.